Cambrian Biopharma is a therapeutics company focused on developing transformative medicines by leveraging the power of biotechnology. It operates as a pipeline company, advancing novel treatments through clinical trials. Cambrian Bio's approach involves creating and supporting multiple therapeutic companies, each targeting different areas of high unmet medical need.

Cambrian Biopharma

Cambrian Bio is a clinical-stage drug development company building the medicines that will modernize healthcare in the 21st century. Our focus lies in creating innovative therapeutics designed to prevent diseases and lengthen healthspan—the period of life spent in good health. 

As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

To date, we have more than a dozen programs (PipeCos) in our pipeline, including Amplifier Therapeutics (developing a peripherally restricted pan-AMPK activator for the treatment of cardiometabolic diseases), Tornado Therapeutics (developing safer, more effective mTOR inhibitors for extended healthspan), and our latest addition, Telos Biotech (enhancing cell therapies to overcome senescence and exhaustion). We also has programs focused on Women’s Health and Aging (Oviva Therapeutics), Fibrosis (Isterian Biotech), and cellular engineering (Vita Therapeutics).

Metric
Company Name	Cambrian Biopharma
Symbol
MSH ID	COM:CAMBRIANBIO
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	34
Website	cambrianbio.com
LinkedIn	cambrianbio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	10.36
28-Day Growth Score	16.39
90-Day Growth Score	14.09
365-Day Growth Score	13.03

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CAMBRIANBIO

Cambrian Biopharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue